Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer
  • Health Canada has approved Puma Biotechnology Inc's PBYI Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.
  • Knight Therapeutics Inc KHTRF has the exclusive right to commercialize Nerlynx in Canada.
  • Nerlynx is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2, and HER4. 
  • Price Action: PBYI shares are down 2.49% at $8.60 during the market session on the last check Tuesday.

Posted In: breast cancerBriefsBiotechNewsPenny StocksHealth CareContractsSmall CapFDAGeneral